Salud financiera de hoja de balance de Alector

Salud financiera controles de criterios 6/6

Alector tiene un patrimonio de los accionistas total de $134.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $621.8M y $487.7M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$548.86m
Patrimonio	US$134.16m
Total pasivo	US$487.67m
Activos totales	US$621.83m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($565.8M) de 0Z2 superan a sus pasivos a corto plazo ($177.9M).

Pasivo a largo plazo: Los activos a corto plazo de 0Z2 ($565.8M) superan a sus pasivos a largo plazo ($309.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 0Z2 está libre de deudas.

Reducción de la deuda: 0Z2 no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 0Z2 tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: 0Z2 dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 7.7% cada año

Salud financiera de hoja de balance de Alector

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold €120k worth of stock

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

Full year 2023 earnings released: US$1.56 loss per share (vs US$1.62 loss in FY 2022)

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million.

New minor risk - Shareholder dilution

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Insufficient new directors

Insufficient new directors

New major risk - Revenue and earnings growth

Co-Founder recently sold €122k worth of stock

Alector, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Third quarter 2023 earnings released: US$0.53 loss per share (vs US$0.56 loss in 3Q 2022)

Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)

Alector, Inc. Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002

Second quarter 2023 earnings released: EPS: US$0.016 (vs US$0.12 in 2Q 2022)

Alector, Inc. to Report Q2, 2023 Results on Aug 03, 2023

First quarter 2023 earnings released: US$0.55 loss per share (vs US$0.54 loss in 1Q 2022)

Alector, Inc. Provides Revenue Guidance for the Year 2023

Co-Founder recently sold €89k worth of stock

Key Executive recently sold €79k worth of stock

Full year 2022 earnings released: US$1.62 loss per share (vs US$0.45 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$1.56 profit in 3Q 2021)

Alector, Inc. Announces Promotion of Clare Hunt to Chief People Officer

Alector, Inc. Announces Resignation of Robert King as Chief Development Officer

Alector, Inc. Initiates Phase 1 Clinical Trial of Al044 for the Treatment of Alzheimer’s Disease

Second quarter 2022 earnings released: EPS: US$0.12 (vs US$0.69 loss in 2Q 2021)

Alector, Inc Developing AL003 to Treat Patients with Alzheimer's Disease as One of Two Programs Pursuant to the Co-Development and Option Agreement

First quarter 2022 earnings released: US$0.54 loss per share (vs US$0.66 loss in 1Q 2021)

Insufficient new directors

Alector, Inc. Announces Appointment of Gary Romano as Chief Medical Officer

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Forecast breakeven date pushed back to 2023

Alector, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2022

Third quarter 2021 earnings released: EPS US$1.56 (vs US$0.67 loss in 3Q 2020)

Insufficient new directors

Alector Announces First Participant Dosed in Phase 2 Study Evaluating Al001 in Amyotrophic Lateral Sclerosis (Als)

Forecast to breakeven in 2021

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$0.69 loss per share (vs US$0.58 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.66 loss per share (vs US$0.54 loss in 1Q 2020)

Advisor has left the company

Revenue misses expectations

Full year 2020 earnings released: US$2.45 loss per share (vs US$1.71 loss in FY 2019)

New 90-day high: €16.40

Alector, Inc. Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease

Alector, Inc. Announces Executive Changes

New 90-day high: €13.70

New 90-day high: €12.40

Revenue misses expectations

Third quarter 2020 earnings released: US$0.67 loss per share

New 90-day low: €8.50

New 90-day low: €9.45

New 90-day low - €10.70

First half earnings released

New 90-day low - €14.50

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera